EUVIMEDEUVIMED entdecken
Crossref

Intravenous vitamin C for COVID-19: no benefit

Drug and Therapeutics Bulletin · 2024

DOI: 10.1136/dtb.2024.000055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug and Therapeutics Bulletin, 2024. Hauptthemen laut MEDLINE: Ascorbic Acid, COVID-19 Drug Treatment, Administration, Intravenous. Die Arbeit nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overview of: LOVIT-COVID Investigators. Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials. JAMA 2023;330:1745-59.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ascorbic AcidCOVID-19 Drug TreatmentAdministration, IntravenousHumansRandomized Controlled Trials as TopicCOVID-19SARS-CoV-2Vitamins

Stichwörter der Autor:innen

Drug-Related Side Effects and Adverse ReactionsHealth Care Quality, Access, and Evaluation

Substanzen

Ascorbic AcidVitamins

Zitieren

APA

(2024). Intravenous vitamin C for COVID-19: no benefit. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.2024.000055

Vancouver

Intravenous vitamin C for COVID-19: no benefit. Drug and Therapeutics Bulletin. 2024. doi:10.1136/dtb.2024.000055

BibTeX
@article{euvimed2024,
  title = {Intravenous vitamin C for COVID-19: no benefit},
  journal = {Drug and Therapeutics Bulletin},
  year = {2024},
  doi = {10.1136/dtb.2024.000055}
}
Kostenlos starten →